Conduit Pharmaceuticals (CDT) announced that the Company received formal notice from The Nasdaq Stock Market that the Company has regained compliance with Nasdaq’s minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq’s stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1). The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CDT:
- Conduit Pharmaceuticals Inc trading halted, news pending
- Upcoming Stock Splits This Week (May 19 to May 23) – Stay Invested
- Conduit Pharmaceuticals Announces Reverse Stock Split
- Conduit Pharmaceuticals announces 1-for-15 reverse stock split
- Conduit Pharmaceuticals receives patent approval for AZD1656